{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Computed tomography scans and/or Positron emission tomography (PET) scans obtained every two cycles to evaluate response using International Workshop Criteria of Complete Response, Partial Response, Progressive Disease, or Stable Disease.","groups":[{"description":"Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m\\^2 intravenously on Days 1, 4, 8, 11.","id":"OG000","title":"Vorinostat + Bortezomib"}],"paramType":"NUMBER","populationDescription":"No analysis done due to early termination resulting from low accrual.","reportingStatus":"POSTED","timeFrame":"Every two 21-day cycles","title":"Number of Patients With Response","type":"PRIMARY","unitOfMeasure":"participants"}